Leaner Genmab A More Likely Buy For GSK?
This article was originally published in The Pink Sheet Daily
Staff cutbacks, dropped programs, and out-licensing plans unveiled.
You may also be interested in...
Approach could encourage front-line Erbitux use in some colorectal patients, Rodman & Renshaw finds after oncologist survey.
Positive top-line Phase III results show response rates as high as 51 percent.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf